Assessing the risk of tumor lysis syndrome associated with the use of antineoplastic agents: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database.

ABSTRACT:

Background

The use of antineoplastic agents is one of the important triggers of tumor lysis syndrome (TLS), but there is still a lack of comprehensive understanding of antineoplastic agents that may trigger TLS and the TLS risk differences between different antineoplastic agents.

Objectives

This study aims to investigate the TLS risk of different antineoplastic agents and provide reference information for clinical practice.

Design

Real-world adverse events data in the FDA Adverse Event Reporting System (FAERS) database were used as the basis for the disproportionality analysis.

Methods

We reviewed the TLS reports in the FAERS database from 2004 to 2022 to summarize an antineoplastic agent list that was reported to trigger TLS, based on which we conducted dispro

SUBMITTER: Li D 

PROVIDER: S-EPMC11380128 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature